Series B · Biotech
Altesa BioSciences raises $75m Series B led by Forbion
Altesa’s oversubscribed financing supports its planned Phase 2b CARDINAL trial of vapendavir.
Capital for the next clinical study
Altesa BioSciences announced an oversubscribed $75m Series B on February 19, 2026. Forbion led the round, with Sanofi joining existing investors Medicxi, Pitango and Atlantic Partners.
The financing was intended to enable the Phase 2b CARDINAL study evaluating vapendavir’s safety and efficacy in people with COPD and rhinovirus infection. At the announcement, Altesa expected the study to start in the second quarter of 2026, making the next clinical evaluation the immediate milestone funded by the round.
Funding history
Series B · This round$75M